Corteva Toekomstige groei
Future criteriumcontroles 1/6
Corteva zal naar verwachting groeien in winst en omzet met respectievelijk 15.4% en 2.7% per jaar. De winst per aandeel zal naar verwachting groeien met 17.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.1% zijn.
Belangrijke informatie
15.4%
Groei van de winst
17.09%
Groei van de winst per aandeel
| Chemicals winstgroei | 18.0% |
| Inkomstengroei | 2.7% |
| Toekomstig rendement op eigen vermogen | 12.06% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 07 May 2026 |
Recente toekomstige groei-updates
Recent updates
Analyse-update • Apr 27
CTVA: Fair Value View Weighs Crop Protection Uncertainty And Planned SpinCo Separation
Corteva's analyst price target has increased by about $2, as analysts cite updated earnings models, a revised fair value of $86.05, a slightly adjusted discount rate, and modest changes to revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Street research on Corteva has been active, with several price target revisions and a mix of ratings changes that give you both supportive and cautious signals to weigh.Analyse-update • Apr 13
CTVA: Fair Value View Balances Crop Protection Risks And Upcoming SpinCo Separation
The analyst price target for Corteva has moved modestly higher to align with a fair value estimate of about $84, as analysts factor in updated earnings models, slightly adjusted revenue growth and profit margin assumptions, and recent price target changes across several firms. Analyst Commentary Recent Street research on Corteva shows a mix of higher price targets and a few rating downgrades, so you are seeing both optimism and caution reflected in the current analyst debate.Analyse-update • Mar 28
CTVA: Crop Protection Uncertainty And SpinCo Separation Will Shape Future Risk Balance
The analyst price target for Corteva has been nudged higher, with a modest fair value uplift to $83.95 as analysts balance a series of recent target increases from multiple firms against more cautious views tied to softer crop protection trends. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on near term fundamentals, especially in crop protection.Analyse-update • Mar 12
CTVA: Mixed Crop Protection Outlook And New SpinCo Plan Will Shape Risk Balance
The analyst price target for Corteva edges higher to $83.33 from $82.76, as analysts factor in slightly firmer long term revenue growth and profit margins, while balancing more cautious views on crop protection trends and a modestly lower discount rate. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on execution in crop protection.Analyse-update • Feb 26
CTVA: Sector Uncertainty And New Ventures Will Shape Forward Risk Balance
Corteva's analyst fair value estimate has edged up to $82.76 from $82.05 as analysts refine their models and price targets following recent earnings updates and a broad wave of upward target revisions across the Street. Analyst Commentary Recent Street research around Corteva reflects an active debate, with several firms adjusting price targets and a mix of upgrades and downgrades around the latest earnings update.Analyse-update • Feb 11
CTVA: Mixed Sector Backdrop And New Ventures Will Shape Future Prospects
Corteva's analyst fair value estimate has increased to $82.05 from $78.43 as analysts factor in slightly stronger revenue growth assumptions, a higher future P/E multiple, and a modestly lower discount rate, even as projected profit margins are trimmed. Analyst Commentary Recent Street research on Corteva is mixed, with several bullish analysts lifting price targets while a few high profile firms turn more cautious.Analyse-update • Jan 26
CTVA: Seed And Crop Protection Split Will Shape Balanced Future Prospects
Narrative Update Analysts have modestly raised their price expectations for Corteva, with the updated fair value estimate moving by about US$0.48 per share. This reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E, and is supported by recent target increases from several firms.Analyse-update • Jan 11
CTVA: Planned Seed And Pesticide Split Will Support Future Earnings Power
Analysts lifted their blended fair value estimate for Corteva by about $0.19 to roughly $77.95 per share, reflecting updated price targets that factor in a mixed backdrop for chemicals and agriculture but continued confidence in the company’s ability to increase earnings. Analyst Commentary Recent research on Corteva reflects a mix of optimism and caution, with price targets clustered in the mid to high US$70s and one outlier in the low US$80s.Seeking Alpha • Jan 10
Corteva: Get Your Piece Of SpinCo As A Stable Portfolio Compounder
Summary Corteva is splitting into two pure-play companies, with the seed segment (SpinCo) offering superior stability and margin profile. I rate CTVA a buy, driven by SpinCo's consistent revenue growth, high operating margins (26%), and robust market position in seeds, especially corn. SpinCo trades at an implied 9.3x EV/EBITDA, below sector and CTVA's historical average, with potential for significant buybacks and dividend increases post-separation. Key risk is U.S. isolationism; deteriorating U.S.-China trade could impact corn and soybean sales, potentially altering the investment thesis. Read the full article on Seeking AlphaAnalyse-update • Dec 18
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
The analyst price target for Corteva has been nudged higher by approximately $0.05 to about $77.76, as analysts factor in a slightly lower discount rate and modestly improved long term growth expectations, despite broadly cautious sector commentary and recent target reductions. Analyst Commentary Street research on Corteva reflects a divided but generally constructive view, with price targets drifting lower but ratings remaining skewed toward positive as investors reassess the company’s post breakup trajectory and near term earnings backdrop.Analyse-update • Dec 03
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
Our analyst price target for Corteva has been trimmed modestly in line with recent Street moves, as analysts factor in lower sector multiples and near term earnings uncertainty around the planned split, while still recognizing the company’s intact innovation engine and long term earnings growth potential. Analyst Commentary Street views on Corteva have become more bifurcated following the announced split, with valuation targets reset lower but ratings broadly supportive of the long term strategic rationale and earnings power.Analyse-artikel • Nov 26
A Look At The Fair Value Of Corteva, Inc. (NYSE:CTVA)
Key Insights Corteva's estimated fair value is US$63.85 based on 2 Stage Free Cash Flow to Equity Current share price...Analyse-update • Nov 19
CTVA: Upcoming Seed And Pesticide Split Will Unlock Shareholder Value
The analyst consensus price target for Corteva has been modestly reduced, slipping from approximately $77.86 to $77.71. Analysts reflect more cautious expectations for earnings growth in light of a mixed agricultural outlook and anticipated impacts from the company's planned business split.Analyse-update • Nov 05
CTVA: Share Split Will Drive Shareholder Value Unlocking Amid Ongoing Business Realignment
Analysts have modestly reduced their average price target for Corteva by approximately $1.20. They cite a more cautious outlook amid challenging crop protection conditions and the company's recent announcement to split into two separate businesses.Analyse-update • Oct 22
Analysts Offer Mixed Views as Corteva Eyes Split and Updates Guidance Amid Modest Valuation Shift
Analysts have modestly reduced their price target for Corteva by about $0.76 to $79.05. They cite uncertainty regarding the company’s planned split and the retention of legacy liabilities, though fundamentals and growth remain largely stable.Analyse-update • Oct 08
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Corteva's analyst price target has been modestly reduced by $0.95 per share. Analysts cite continued uncertainty around the planned corporate split and complex crop protection market dynamics.Analyse-update • Sep 04
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Analysts maintained their price target for Corteva at $80.76, citing margin expansion and EBITDA growth driven by successful innovation, favorable market fundamentals, and strong execution. Analyst Commentary Ongoing cost reductions, successful innovation, and strong execution are driving margin expansion and double-digit EBITDA growth.Analyse-artikel • Aug 26
Corteva's (NYSE:CTVA) Shareholders Will Receive A Bigger Dividend Than Last Year
Corteva, Inc. ( NYSE:CTVA ) will increase its dividend from last year's comparable payment on the 15th of September to...Analyse-artikel • Aug 01
Corteva's (NYSE:CTVA) Shareholders Will Receive A Bigger Dividend Than Last Year
Corteva, Inc. ( NYSE:CTVA ) will increase its dividend on the 15th of September to $0.18, which is 5.9% higher than...Analyse-artikel • Jul 28
Investors Interested In Corteva, Inc.'s (NYSE:CTVA) Earnings
With a price-to-earnings (or "P/E") ratio of 43.9x Corteva, Inc. ( NYSE:CTVA ) may be sending very bearish signals at...Analyse-artikel • Jul 14
We Think Corteva (NYSE:CTVA) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 21
Corteva: Upgraded To Strong Buy On Tariffs, Currency Tailwinds, Strong Guidance
Summary Upgrading Corteva from Buy to Strong Buy due to macro conditions, including tariff-induced supply shocks, rising commodity prices, and currency tailwinds. Corteva's diversified supply chain and local production in seeds position it to benefit from regionalization and potential inflationary pressures in the agricultural sector. Strong Q4 earnings, record operating EBITDA margin, and robust free cash flow support the bullish outlook, with significant shareholder returns through dividends and buybacks. Improved valuation at 20x forward earnings, solid balance sheet, and technical indicators suggest potential for further upside in the current market environment. Read the full article on Seeking AlphaSeeking Alpha • Mar 30
Pure Market Inefficiency In Corteva Preferreds Pricings
Summary This article explores a market inefficiency in fixed-income securities, specifically between Corteva's $4.50 and $3.50 Series Cumulative Preferred Stocks. We identified an arbitrage opportunity due to technical buying, making it an ideal pair trade with identical issues from the same company. On 02/09/2025, we recommended CTA-B for our investment-grade long-duration portfolio. On 02/10/2025, technical high-volume buying in CTA-A turned our initial investment idea into a pair trade. This pair trade highlights how technical factors can create profitable opportunities in fixed-income securities, especially among identical issues from the same issuer. Read the full article on Seeking AlphaSeeking Alpha • Feb 09
CTA.PR.B: An Undervalued Investment-Grade Opportunity From Corteva
Summary CTA-B offers a 6.32% current yield, making it an attractive investment-grade preferred stock with solid financial backing from Corteva, Inc. Corteva, Inc.'s strong financial health and low leverage ensure the safety of uninterrupted dividend distributions for CTA-B shareholders. Comparative analysis shows CTA-B is undervalued, offering a potential 10% capital appreciation relative to its peers and Corteva's OTC bonds. Corteva's BBB credit rating and low-risk perception in the bond market further reinforce the security and value of investing in CTA-B. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Corteva: A Wide-Moat Play On Commodity Prices
Summary Corteva is a strong defensive play for stagflation with its wide economic moat in seeds, providing exposure to agricultural commodities and a growing dividend. The company has shown impressive performance since its 2019 spin-off, with growth in gross profits and operating income exceeding revenue growth, reflecting strong operating efficiency. Corteva faces risks such as regulatory and ESG concerns, pricing pressure in crop protection, and currency fluctuations, but remains a resilient and diversified investment. I rate Corteva a "Buy" for its defensive characteristics, allowing investors to gain commodity exposure as a best-in-breed operator. Read the full article on Seeking AlphaSeeking Alpha • Nov 10
Corteva Q3: Lower Commodity And Raw Material Costs Ahead, Potential Margin Expansion
Summary I reiterate a 'Buy' rating for Corteva with a fair value target of $68 per share, driven by anticipated margin expansion and end-market recovery. Corteva's Q3 results showed weak growth in Latin America, but benefits from raw material cost deflation and cost management are expected to enhance margins in FY25. Management forecasts a flat crop protection market for FY25, with significant cost reductions from lower seed commodity costs and deflationary raw materials. Despite near-term price/mix challenges, lower input costs could be a major catalyst for margin expansion, supporting the stock's undervaluation and 'Buy' recommendation. Read the full article on Seeking AlphaWinst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 19,401 | 2,308 | 2,572 | 3,221 | 12 |
| 12/31/2027 | 18,892 | 2,098 | 2,390 | 2,944 | 19 |
| 12/31/2026 | 18,257 | 1,781 | 256 | 2,064 | 19 |
| 3/31/2026 | 17,889 | 1,252 | 2,046 | 2,624 | N/A |
| 12/31/2025 | 17,401 | 1,193 | 2,815 | 3,406 | N/A |
| 9/30/2025 | 17,469 | 1,681 | 2,654 | 3,204 | N/A |
| 6/30/2025 | 17,177 | 1,469 | 2,594 | 3,141 | N/A |
| 3/31/2025 | 16,833 | 1,142 | 2,102 | 2,645 | N/A |
| 12/31/2024 | 16,908 | 851 | 1,548 | 2,145 | N/A |
| 9/30/2024 | 16,637 | 670 | 1,746 | 2,345 | N/A |
| 6/30/2024 | 16,901 | 874 | 1,503 | 2,110 | N/A |
| 3/31/2024 | 16,834 | 698 | 1,879 | 2,471 | N/A |
| 12/31/2023 | 17,226 | 929 | 1,174 | 1,769 | N/A |
| 9/30/2023 | 17,344 | 1,119 | -143 | 414 | N/A |
| 6/30/2023 | 17,531 | 1,112 | -543 | -6 | N/A |
| 3/31/2023 | 17,738 | 1,234 | -286 | 291 | N/A |
| 12/31/2022 | 17,455 | 1,205 | 267 | 872 | N/A |
| 9/30/2022 | 17,109 | 1,401 | 780 | 1,400 | N/A |
| 6/30/2022 | 16,703 | 1,760 | 1,127 | 1,749 | N/A |
| 3/31/2022 | 16,078 | 1,776 | 1,332 | 1,947 | N/A |
| 12/31/2021 | 15,655 | 1,812 | 2,154 | 2,727 | N/A |
| 9/30/2021 | 15,383 | 1,756 | 1,895 | 2,482 | N/A |
| 6/30/2021 | 14,875 | 1,330 | 1,748 | 2,290 | N/A |
| 3/31/2021 | 14,439 | 1,075 | 1,560 | 2,044 | N/A |
| 12/31/2020 | 14,217 | 736 | 1,589 | 2,064 | N/A |
| 9/30/2020 | 13,993 | 594 | 1,687 | 2,136 | N/A |
| 6/30/2020 | 14,041 | 470 | 758 | 1,289 | N/A |
| 3/31/2020 | 14,406 | 179 | 53 | 681 | N/A |
| 12/31/2019 | 13,846 | -288 | N/A | 1,070 | N/A |
| 9/30/2019 | 13,678 | -1,322 | N/A | 960 | N/A |
| 6/30/2019 | 13,714 | -6,453 | N/A | 985 | N/A |
| 3/31/2019 | 12,921 | -6,965 | N/A | -263 | N/A |
| 12/31/2018 | 14,287 | -6,813 | N/A | 483 | N/A |
| 9/30/2018 | 14,299 | -3,538 | N/A | N/A | N/A |
| 6/30/2018 | 14,220 | 1,261 | N/A | N/A | N/A |
| 3/31/2018 | 14,230 | 1,898 | N/A | N/A | N/A |
| 12/31/2017 | 10,684 | 2,081 | N/A | -275 | N/A |
| 12/31/2016 | 14,041 | 503 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei CTVA ( 15.4% per jaar) ligt boven de spaarquote ( 3.5% ).
Winst versus markt: De winst van CTVA ( 15.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.4% per jaar).
Hoge groeiwinsten: De winst van CTVA zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van CTVA ( 2.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.4% per jaar).
Hoge groei-inkomsten: De omzet van CTVA ( 2.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen CTVA zal naar verwachting over 3 jaar laag zijn ( 12.1 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/07 08:31 |
| Aandelenkoers aan het einde van de dag | 2026/05/07 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Corteva, Inc. wordt gevolgd door 39 analisten. 19 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Argus Research Company |
| Benjamin Theurer | Barclays |
| Benjamin Theurer | Barclays |